Glycemic Control Status and Long-Term Clinical Outcomes in Diabetic Chronic Total Occlusion Patients: An Observational Study

Table 4

Estimated Kaplan–Meier event rates in subgroups of propensity score-matched population.

	CTO-SR				CTO-NSR
	HbA1c < 7.0	HbA1c ≥ 7.0	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	HbA1c < 7.0	HbA1c ≥ 7.0	Unadjusted HR (95% CI)	Adjusted HR (95% CI)
MACE	53 (27.7)	63 (32.3)	1.254 (0.781–2.015)	1.284 (0.784–2.102)	66 (40.7)	77 (48.7)	1.566 (0.996–2.462)	1.826 (1.112–2.999)
Cardiac death	9 (4.7)	7 (3.6)	0.650 (0.210–2.011)	0.581 (0.172–1.959)	8 (4.9)	8 (5.1)	1.165 (0.422–3.216)	1.514 (0.422–5.433)
Repeat revascularization	43 (22.5)	56 (28.7)	1.601 (0.926–2.766)	1.730 (0.980–3.055)	56 (34.6)	67 (42.4)	1.627 (0.969–2.733)	1.906 (1.091–3.330)
Repeat nonfatal MI	8 (4.2)	8 (4.1)	0.935 (0.314–2.785)	0.992 (0.323–3.043)	13 (8.0)	8 (5.1)	0.351 (0.112–1.103)	0.242 (0.072–0.817)
All-cause death	12 (6.3)	10 (5.1)	0.738 (0.279–1.952)	0.804 (0.288–2.248)	12 (7.4)	13 (8.2)	1.321 (0.579–3.015)	1.133 (0.425–3.022)
TVR	22 (11.5)	31 (15.9)	1.207 (0.567–2.570)	1.342 (0.590–3.052)	35 (21.6)	45 (28.5)	1.995 (0.987–4.034)	2.194 (1.059–4.548)

Adjusted covariates: age, CKD, LAD-CTO, LCX-CTO, LVEF, PVD, Rentrop grade ≥ 2, RWMA, sex, single-vessel disease, systolic heart failure, SYNTAX score, and triple-vessel disease. CKD: chronic kidney disease; CI: conference interval; HR: hazard ratio; LAD-CTO: left anterior descending artery-chronic total occlusion; LCX-CTO: left circumflex chronic total occlusion; LVEF: left ventricular ejection fraction; MACE: major adverse cardiac events, a composite of cardiac death, repeat revascularization, and repeat nonfatal MI; PVD: peripheral vascular disease; RWMA: regional wall motion abnormalities; SYNTAX: percutaneous coronary intervention with taxus and cardiac surgery; TVR: target vessel revascularization.